Foundation for Biomedical Research and Innovation at KobeNEWS
- Monthly
-
2024.04.01
Shuh Narumiya, M.D., Ph.D., appointed as the President of the Foundation for Biomedical Research and Innovation at Kobe (FBRI) and Hisashi Ietsugu, Sysmex Corporation Chairperson and Group CEO, appointed as the FBRI’s newly created position of the Chairman -
2024.03.28 Pressrelease
We have executed a collaborative research agreement for vascular regeneration products derived from human hematopoietic stem cells by Celaid Therapeutics -
2024.02.08 Pressrelease
RNA Analysis of Circulating Leukocytes in Patients with Alzheimer’s Disease: our research team’s findings published in Journal of Alzheimer's Disease on January 22, 2024 -
2023.12.25 Pressrelease
BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state: our research team’s findings published in Nature Communications on December 16, 2023 -
2023.11.30 Pressrelease
Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease: our research team’s findings published in Neuroprotection on November 21, 2023 -
2023.07.27 Pressrelease
SETBP1 is dispensable for normal and malignant hematopoiesis: our research team’s findings published ‘Leukemia’ on July 18, 2023 -
2023.01.16 Pressrelease
Professor Akio Ohta’s research group defined immunosuppressive anti-PD-1 antibodies and published in Science Immunology on January 13, 2023 -
2022.07.01
FBRI’ research on Acute Myeloid Leukemia publish in Blood -
2022.05.13 Pressrelease
The research team of the Department of Hematology-Oncology, Institute of Biomedical Research and Innovation and the University of Tokyo elucidates a novel regulatory mechanisms by which MDS cells inhibit normal hematopoiesis, published in Cell Reports on May 10, 2022
-
2022.02.03
Dr. Taguchi Akihiko’s research was published in Frontiers in Aging Neuroscience
(Published: February 3, 2022)